

References

References marked with an asterisk indicate studies included in the meta-analysis.

- *Alam, S., Ghosh, J., Mustafa, G., Kamal, M., & Ahmad, N. (2018). Effect of SGT on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial. *Hepatology Medicine*, 10, 23-31. doi: 10.2147/HMER.S158053. eCollection 2018.
- *Alam, S., Kabir, J., Mustafa, G., Gupta, U., Hasan, S. K., & Alam, A. K. (2016). Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. *Saudi Journal Gastroenterology*, 22(1), 69-76. doi: 10.4103/1319-3767.173762.
- Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999). Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. *American Journal Gastroenterology*, 94(9), 2467-2474.
- Connolly, J. J., Ooka, K., & Lim, J. K. (2018). Future pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of phase 2 and 3 trials. *Journal of Clinical and Translational Hepatology*, 6(3), 264-275.
- *Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., & Tio, F. (2016). Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and

PHARMACOLOGICAL INTERVENTIONS IN NON-ALCOHOLIC STEATOHEPATITIS

- prediabetes or type 2 diabetes mellitus: A randomized trial. *Annals Internal Medicine*, 165(5), 305-315. doi: 10.7326/M15-1774. Epub 2016 Jun 21.
- Edmison, J., & McCullough, A., G. Pathogenesis of non- alcoholic steatohepatitis: Human data. (2007). *Clinical Liver Diseases*, 11(1), 75-104, ix.
- Eguchi, Y., Hyogo, H., Ono, M., Mizuta, T., Ono, N., Fujimoto, K., & Chayama, K. (2012). Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 and 2010 in Japan: A multicenter large retrospective study. *Journal Gastroenterology*, 47(5), 586-595. doi: 10.1007/s00535-012-0533-z. Epub 2012 Feb 11.
- Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., & Colombo, M. (2018). Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. *Journal Hepatology*, 69(4), 896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.
- Hashimoto, E. (2007). Pathology diagnosis of NAFLD. *Chiryo*, 89, 1656-1662.
- Higgins, J. P. T., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, M., Oxman, A. D., Savović, J. (2011). *The Cochrane Collaboration's tool for assessing risk of bias in randomised trials*. BMJ, 343. doi.org/10.1136/bmj.d5928 (Published 18 October 2011)

PHARMACOLOGICAL INTERVENTIONS IN NON-ALCOHOLIC STEATOHEPATITIS

- *Joy, T. R., McKenzie, C. A., Tirona, R. G., Summers, K., Seney, S., Chakrabarti, S., & Malhotra, N. (2017). SGT in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. *World Journal Gastroenterology*, 23(1), 141-150. doi: 10.3748/wjg.v23.i1.141.
- Juluri, R., Vuppalanchi, R., Olson, J., Ünalp, A., Natta, M.L.V., Cummings, O.W., & Tonascia, J. (2011). Generalizability of the NASH CRN histological scoring system for nonalcoholic fatty liver disease. *Journal Clinical Gastroenterology*, 45(1), 55–58. doi: 10.1097/MCG.0b013e3181dd1348
- Larter, C. Z., & Farrell, G. C. (2006). Insulin resistance, adiponectin, and cytokines in NASH: Which is the best target to treat? *Journal Hepatology*. 44(2), 253-261. Epub 2005 Dec 1.
- *Le,T. A., Chen, J., Changchien, C., Peterson, M. R., Kono, Y., Patton, H., & Cohen, B. L. (2012). Effect of colesvelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A Randomized controlled trial. *Hepatology*, 56(3), 922-932. doi: 10.1002/hep.25731. Epub 2012 Jul 2.
- *Leuschner, U. F., Lindenthal, B., Herrmann, G., Arnold, J. C., Rössle, M., Cordes, H. J., Zeuzem, S. (2010). High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double-blind, randomized, placebo-controlled trial. *Hepatology*, 52(2), 472-479. doi: 10.1002/hep.23727.

PHARMACOLOGICAL INTERVENTIONS IN NON-ALCOHOLIC STEATOHEPATITIS

Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A.,

Clarke, M. (2009). The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and elaboration. *BMJ*, 339. doi.org/10.1136/bmj.b2700 (Published 21 July 2009)

Lillis, J., & Kendra, K. E. (2014). Acceptance and Commitment Therapy for weight control: Model, evidence, and future directions. *Journal Contextual Behavioral Science*, 3(1), 1-7.

*Loomba, R., Sirlin, C. B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., Richard, E. (2015). Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial). *Hepatology*, 61(4), 1239-1250. doi: 10.1002/hep.27647. Epub 2015 Feb 27.

Matteoni, C. A., Younossi, Z. M., Gramlich, T., Boparai, N., Liu Y. C., & McCullough, A. J. (1999). Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. *Gastroenterology*, 116(6), 1413-1419.

Michitaka, K., Nishiguchi, S., Aoyagi, Y., Hiasa, Y., Tokumoto, Y., & Onji, M. (2010). Etiology of liver cirrhosis in Japan: A nationwide survey. *Journal Gastroenterology*, 45(1), 86-94. doi: 10.1007/s00535-009-0128-5. Epub 2009 Sep 30.

PHARMACOLOGICAL INTERVENTIONS IN NON-ALCOHOLIC STEATOHEPATITIS

- Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2010). A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. *Hepatology*, 52(1), 79-104. doi: 10.1002/hep.23623.
- Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003). Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. *Hepatology*, 38(4), 1008-1017.
- Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., & Chalasani, N. (2015). Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. *Lancet*, 385(9972), 956-965. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7.
- *Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann-Heurtier, A., Serfaty, L., & Podgevin, P. (2008). Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. *Gastroenterology*, 135(1), 100-110. doi: 10.1053/j.gastro.2008.03.078. Epub 2008 Apr 8.
- Santiago-Rolón, A., Purcell, D., Rosado, K., & Toro, D. H. (2015). A comparison of Brunt's criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a proposed NAS scoring that includes fibrosis in non-alcoholic fatty liver disease staging. *Puerto Rico Health Sciences Journal*, 34(4), 189-94Stickel, F., & Seitz, H.

PHARMACOLOGICAL INTERVENTIONS IN NON-ALCOHOLIC STEATOHEPATITIS

- K. (2010). Alcoholic steatohepatitis. *Best Practices Research Clinical Gastroenterology*, 24(5), 683-693. doi: 10.1016/j.bpg.2010.07.003.
- *Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., & Neuschwander-Tetri, B. A. (2010). Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *New England Journal Medicine*, 362(18), 1675-1685. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28
- Tokushige, K., Hashimoto, E., Horie, Y., Taniai, M., & Higuchi, S. (2011). Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: Report of the nationwide survey. *Journal Gastroenterology*, 46(10), 1230-1237. doi: 10.1007/s00535-011-0431-9. Epub 2011 Jul 13
- *Van Wagner, L. B., Koppe, S. W., Brunt, E. M., Gottstein, J., Gardikiotes, K., Green, R. M., & Rinella, M. E. (2011). Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. *Annals Hepatology*, 10(3), 277-286.
- Watanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., & Seike, M. (2015). Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *Journal Gastroenterology*, 50(4), 364-377. doi: 10.1007/s00535-015-1050-7. Epub 2015 Feb 24.
- Younossi, Z. M., Stepanova, M., Rafiq, N., Makhlof, H., Younoszai, Z., Agrawal, R., & Goodman, Z. (2011). Pathologic criteria for nonalcoholic steatohepatitis:

interprotocol agreement and ability to predict liver-related mortality. *Hepatology*, 53(6), 1874-1882. doi: 10.1002/hep.24268. Epub 2011 May 14.

*Zein, C. O., Yerian, L. M., Gogate, P., Lopez, R., Kirwan, J. P., Feldstein, A. E., McCullough, A. J. (2011). Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. *Hepatology*, 54(5):1610-1619. doi: 10.1002/hep.24544. Epub 2011 Aug 24.